Theradiag has announced that it has entered into a partnership agreement with Hospira regarding the supply of LISA-TRACKER’s CE-marked infliximab monitoring kit.
To give clinicians and patients the highest level of biological information regarding the treatment with the biosimilar of infliximab, Hospira will be providing LISA TRACKER’s infliximab assays and anti-infliximab antibodies assays kits in tenders awarded in Europe, Canada and Australia. Hospira has selected Theradiag as its exclusive provider of monitoring tools.
Theradiag will supply Hospira with LISA TRACKER monitoring kits and will also ensure installation and training in laboratories and provide information and follow-up with clinicians on behalf of Hospira. LISA TRACKER’s infliximab kits have been validated for use with Inflectra®.
“This partnership agreement marks a significant change in how pharmaceutical companies view theranostics and a formidable opportunity to promote the monitoring of biotherapies. For the first time, a pharmaceutical company will be pairing our monitoring kits with their treatments. This will build greater awareness within the medical and patients’ community regarding the benefits of biotherapy monitoring, which improve patient care while cutting healthcare spending. We anticipate this will also have a very favorable impact on future sales of LISA TRACKER” commented Michel Finance, Chief Executive Officer of Theradiag.
Hospira commercializes Inflectra®, the first biosimilar monoclonal antibody to be approved by the European Medicines Agency. It is a biologic equivalent to infliximab (Remicade®), which is indicated for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriasis and psoriatic arthritis. Remicade® generated 10.1 billion dollars worldwide sales in 2014.